[1]石以石则,李婷婷,陈 威,等.化痰祛瘀法联合西药治疗胃癌前病变的Meta分析[J].医学信息,2022,35(07):99-104.[doi:10.3969/j.issn.1006-1959.2022.07.024]
　SHI Yi-shi-ze,LI Ting-ting,CHEN Wei,et al.Meta-analysis of Dissipating Phlegm and Removing Blood Stasis Combined with Western Medicine in the Treatment of Gastric Precancerous Lesions[J].Medical Information,2022,35(07):99-104.[doi:10.3969/j.issn.1006-1959.2022.07.024]
点击复制

化痰祛瘀法联合西药治疗胃癌前病变的Meta分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年07期
页码:
99-104
栏目:
论著
出版日期:
2022-04-01

文章信息/Info

Title:
Meta-analysis of Dissipating Phlegm and Removing Blood Stasis Combined with Western Medicine in the Treatment of Gastric Precancerous Lesions
文章编号:
1006-1959（2022）07-0099-06
作者:
石以石则; 李婷婷; 陈 威; 等
（1.贵州中医药大学研究生院，贵州 贵阳 550000；2.贵州中医药大学第二附属医院消化内科，贵州 贵阳 550000）
Author(s):
SHI Yi-shi-ze; LI Ting-ting; CHEN Wei; et al.
(1.Graduate School of Guizhou University of Traditional Chinese Medicine,Guiyang 550000,Guizhou,China;2.Department of Gastroenterology,the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine,Guiyang 550000,Guizhou,China)
关键词:
化痰祛瘀法; 胃癌前病变; 胃黏膜萎缩; 胃脘痛
Keywords:
Dissipating phlegm and removing blood stasis; Precancerous lesions of gastric cancer; Gastric mucosa atrophy; Abdominal pain
分类号:
R259；R273
DOI:
10.3969/j.issn.1006-1959.2022.07.024
文献标志码:
A
摘要:
目的 系统评价化痰祛瘀法联合西药治疗胃癌前病变的临床疗效及安全性。方法 检索知网、维普、万方、PubMed数据库中“化痰祛瘀法联合西药治疗胃癌前病变”的相关文献，检索时限为建库至2021年11月。据纳入、排除标准筛选文献，提取所需资料数据，采用Revman 5.4软件进行分析，评价单纯西药与化痰祛瘀法联合西药治疗胃癌前病变的临床疗效、胃脘痛症状改善情况、血清胃蛋白酶原水平、胃黏膜病理变化以及不良反应发生率。结果 纳入8个研究，745例患者，其中治疗组（化痰祛瘀法联合西药）375例，对照组（西药）370例；Meta分析显示，与对照组比较，治疗组胃黏膜病理变化改善[胃黏膜萎缩（MD=-0.76，95%CI：-1.40~-0.13）、肠上皮化生（MD=-0.51，95%CI：-0.74~-0.28）、异型增生（MD=-0.53，95%CI：-0.76~-0.30）]及胃脘痛症状改善（MD=-0.78，95%CI：-1.28~-0.28）优于对照组，临床总有效率高于对照组（RR=1.25，95%CI：1.15~1.35），差异有统计学意义（P＜0.05）；两组血清PGⅠ（MD=18.08，95%CI：0.08~36.08）、PGⅡ（MD=1.21，95%CI：-5.44~7.85）水平及不良反应发生率（RR= 1.67，95%CI：0.42~6.66）比较，差异无统计学意义（P＞0.05）。结论 化痰祛瘀法联合西药治疗胃癌前病变能更好的提高临床总有效率，改善胃脘痛症状、胃黏膜病理改变及血清PGⅠ、PGⅡ水平，具有较好的安全性。
Abstract:
Objective To evaluate the clinical efficacy and safety of dissipating phlegm and removing blood stasis combined with Western medicine in the treatment of precancerous lesions of gastric cancer.Methods The relevant literature of “dissipating phlegm and removing blood stasis combined with Western medicine in the treatment of precancerous lesions of gastric cancer” in CNKI, VIP, Wanfang and PubMed databases were retrieved, and the retrieval time was from database establishment to November 2021. According to the inclusion and exclusion criteria, the literature was screened, and the required data were extracted. Revman 5.4 software was used to analyze and evaluate the clinical efficacy of simple Western medicine and dissipating phlegm and removing blood stasis combined with Western medicine in the treatment of precancerous lesions of gastric cancer, the improvement of epigastric pain symptoms, serum pepsinogen level, pathological changes of gastric mucosa and the incidence of adverse reactions.Results A total of 745 patients were included in eight studies, including 375 patients in the treatment group (dissipating phlegm and removing blood stasis combined with Western medicine) and 370 patients in the control group (western medicine). Meta-analysis showed that compared with the control group, the improvement of gastric mucosal pathological changes [gastric mucosal atrophy (MD=-0.76, 95%CI: -1.40 to-0.13), intestinal metaplasia (MD=-0.51, 95%CI:-0.74 to -0.28), dysplasia (MD=-0.53, 95%CI: -0.76 to -0.30)] and epigastric pain symptoms (MD=-0.78, 95%CI: -1.28 to -0.28) in the treatment group were better than those in the control group, and the total clinical response rate was higher than that in the control group (RR=1.25, 95%CI: 1.15 to 1.35), the difference was statistically significant (P<0.05); there was no significant difference in serum PGⅠ(MD=18.08, 95%CI: 0.08 to 36.08), PGⅡ (MD=1.21, 95%CI:-5.44 to 7.85) levels and incidence of adverse reactions (RR=1.67, 95%CI:0.42 to 6.66) between the two groups (P>0.05).Conclusion Dissipating phlegm and removing blood stasis combined with Western medicine in the treatment of precancerous lesions of gastric cancer can better improve the clinical total effective rate, improve epigastric pain symptoms, gastric mucosal pathological changes and serum PGⅠ, PGⅡ levels, with good safety.

参考文献/References:

[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.[2]王萍,李鹏,陈萦晅,等.中国整合胃癌前病变临床管理指南[J].胃肠病学,2021,26(2):91-111.[3]张瑞峰.胃低级别上皮内瘤变的临床特点及病变发展危险因素分析[J].内蒙古医学杂志,2021,53(10):1245-1247.[4]Kubo A,Kurtovich E,McGinnis M,et al.A randomized controlled trial of mhealth mindfulness intervention for cancer patients and informal cancer caregivers:a feasibility study within an integrated health care delivery system[J].Integr Cancer Ther,2019(18):1534735419850634.[5]王晓瑜,徐艳,吴云林.胃癌前病变逆转的中西医治疗探讨[J].国际消化病杂志,2020,40(6):367-370.[6]苏泽琦,张文君,张雨珊,等.慢性胃炎恶性转化过程证候、证素演变规律[J].现代中医临床,2017,24(6):9-14.[7]黄钰萍,王熠慧,安振涛,等.胃癌前病变中医证型分类探讨[J].中医学报,2021,36(2):406-409.[8]崔国良,冯小可,吴娟,等.化痰消瘀方治疗胃癌前病变的分子机制研究[J].中药药理与临床,2021,37(1):172-179.[9]程丛彪,李娜.益气化瘀方联合西药治疗慢性萎缩性胃炎的临床观察[J].中国中医药科技,2019,26(5):772-773.[10]肖曼丽.化痰消瘀剂治疗胃部癌前病变的效果评价[J].实用医院临床杂志,2019,16(4):92-94.[11]孔岩君,魏睦新.化痰消瘀汤剂治疗HP阳性萎缩性胃炎的疗效观察[J].中国中医基础医学杂志,2015,21(9):1171-1173.[12]胡平,郝传铮.化痰消瘀方对慢性萎缩性胃炎合并肠上皮化生患者的疗效及对胃镜病理的影响[J].中药材,2019,42(8):1934-1937.[13]刘少康,朱正午.化痰消瘀汤联合西药治疗慢性萎缩性胃炎45例疗效观察[J].新疆中医药,2019,37(5):9-11.[14]王岚,魏睦新.化痰消瘀汤联合西药治疗胃癌前病变疗效及对胃蛋白酶原指标的影响[J].现代肿瘤医学,2020,28(8):1323-1326.[15]冯小可,林贞妍,刘璇,等.化痰消瘀方逆转胃癌前病变效果及对胃液外泌体miRNA表达的影响[J].现代中西医结合杂志,2021,30(9):936-939,970.[16]孙涛,周兰,朱玉,等.益胃化浊方联合叶酸片、亮菌口服溶液治疗胃癌前病变30例[J].中医临床研究,2019,11(21):74-77.[17]曹婷婷,叶柏.胃癌前期病变中医病机的研究概况[J].光明中医,2014,29(12):2682-2683.[18]周晔禄,杨志宏.沈舒文辨治胃癌前病变临床经验采撷[J].上海中医药杂志,2018,52(6):1-4,29.[19]Guan ZH,Chen J,Li XL,et al.Tanshinone IIA induces ferroptosis in gastric cancer cells through p53-mediated SLC7A11 down-regulation [J].Biosci Rep,2020,40(8):BSR20201807.[20]石雪迎,赵凤志,戴欣,等.三七对大鼠实验性慢性萎缩性胃炎癌前病变作用的形态学观察[J].北京中医药大学学报,1999(6):45-47.[21]袁冲,吴和珍,刘博,等.基于网络药理学的半夏抗炎活性成分及作用机制研究[J].中华中医药学刊,2020,38(9):150-153,275-276.[22]董鑫,徐伟玲,申俊丽,等.生半夏在恶性肿瘤治疗中的研究与应用[J].中医药学报,2019,47(4):106-108.[23]庞张祥.薏苡仁拆分组分对脾虚水湿不化大鼠胃肠功能及利尿作用影响的性味药理学评价[D].济南:山东中医药大学,2016.[24]王博龙.基于网络药理学的康莱特注射液3种主要成分抗肿瘤机制研究[J].中国现代应用药学,2019,36(1):58-63.[25]Shen P,Liu MH,Ng TY,et al.Differential effects of isoflavones,from Astragalus membranaceus and Pueraria thomsonii,on the activation of PPARalpha,PPARgamma,and adipocyte differentiation in vitro[J].J Nutr,2006,136(4):899-905.[26]文采,肖明娜,朴善英.PG、MG7-Ag联合G-17检测对胃癌前病变、胃癌的诊断及鉴别诊断[J].分子诊断与治疗杂志,2020,12(11):1488-1492.[27]龙丹,章杰,钟冬水,等.血清胃蛋白酶原与尿素14C呼气试验检测在胃癌及其癌前病变筛查中的价值[J].中国医药科学,2017,7(17):9-11,25.

相似文献/References:

[1]铉 力,王晓红,胡 兵.胡兵教授治疗胃癌前病变的经验举隅[J].医学信息,2020,33(03):158.[doi:10.3969/j.issn.1006-1959.2020.03.052]
　XUAN Li,WANG Xiao-hong,HU Bing.Professor Hu Bing’s Experience in Treating Gastric Precancerous Lesion[J].Medical Information,2020,33(07):158.[doi:10.3969/j.issn.1006-1959.2020.03.052]
[2]陈 璐.温阳健脾汤治疗慢性萎缩性胃炎癌前病变的疗效及安全性[J].医学信息,2021,34(01):167.[doi:10.3969/j.issn.1006-1959.2021.01.046]
　CHEN Lu.Efficacy and Safety of Wenyang Jianpi Soup in the Treatment of CAG-PLGC[J].Medical Information,2021,34(07):167.[doi:10.3969/j.issn.1006-1959.2021.01.046]

更新日期/Last Update: 1900-01-01